Background Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by ...

Acute-on-chronic liver failure (ACLF) exhibits etiological heterogeneity across regions, with hepatitis B virus (HBV)-related ACLF predominant in China and alcohol-related ACLF dominating Western ...

Of 1.3 million participants in the MWS with a median follow-up of 21.4 years, 2,765 (o.21%) developed liver cancer, with no association emerging between ever-use of oral contraceptives and liver ...

A research team led by Professor Takuya Yamamoto (Department of Life Science Frontiers) and Professor Yasuhiro Yamada at the University of Tokyo has developed a novel in vivo system that reveals how ...

Compassionate-use lurbinectedin demonstrates modest yet consistent efficacy and is well tolerated in patients with ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

A multicenter study evaluating lurbinectedin in patients with extensive-stage small cell lung cancer who received second-line ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

With greater investment to improve the scalability and consistency of manufacturing, EV-based medicine is poised to shape ...

With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status ...